Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02445612 · ClinicalTrials.gov registry record
Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients
A clinical trial of Stargardt's Macular Dystrophy, sponsored by Astellas Institute for Regenerative Medicine.
- Completed
- Registry status
- 13
- Enrollment target
- 3
- Study locations
NCT02445612 is a study of Stargardt's Macular Dystrophy that has completed, run by Astellas Institute for Regenerative Medicine. The registered enrollment target is 13 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT02445612, a study of Stargardt's Macular Dystrophy, has completed, sponsored by Astellas Institute for Regenerative Medicine.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced Stargardt's Macular Dystrophy (SMD) from one to five years following the surgical procedure to implant the MA09-hRPE cells.
Conditions Studied
Interventions
- BIOLOGICAL MA09-hRPE
Study Locations (3)
California
- Jules Stein Eye Institute, UCLA School of Medicine - Los Angeles
Florida
- Bascom Palmer Eye Institute - Miami
Pennsylvania
- Wills Eye Institute-Mid Atlantic Retina - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-07-11 |
| Est. Completion | 2019-06-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02445612
The ClinicalTrials.gov registry entry for NCT02445612 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Institute for Regenerative Medicine, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stargardt's Macular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which MA09-hRPE is the first listed.
NCT02445612 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02445612 about?
NCT02445612 is a clinical study titled "Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients". The purpose of this study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced Stargardt's Macular Dystrophy (SMD) from one to five years following the surgical procedure to implant the MA09-hRPE cells.
What is the current status of trial NCT02445612?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2012-07-11. Estimated completion is 2019-06-21.
What conditions does trial NCT02445612 study?
This clinical trial studies the following conditions: Stargardt's Macular Dystrophy.
What interventions are being tested in trial NCT02445612?
The interventions under investigation include: MA09-hRPE (BIOLOGICAL).
Who is sponsoring clinical trial NCT02445612?
This trial is sponsored by Astellas Institute for Regenerative Medicine, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02445612 being conducted?
This trial has 3 study locations across California, Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.